Skip to main content

Table 3 Dyspnoea, health-related quality of life and use of rescue medication up to Week 26

From: Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial

  NVA237 50 μg Placebo
TDI focal score   
   Least squares mean (± SE) 1.84 ± 0.257 0.80 ± 0.294
   Least squares mean difference (± SE) 1.04 ± 0.235
   p-value < 0.001
SGRQ score   
   Baseline mean 46.11 46.34
   Least squares mean (± SE) 39.50 ± 0.813 42.31 ± 0.992
   Least squares mean difference (± SE) -2.81 ± 0.961
   p-value 0.004
Rescue medication use, puffs/day   
   LSM change from baseline (± SE) -1.21 ± 0.122 -0.75 ± 0.156
   Least squares mean difference (± SE) -0.46 ± 0.164
   p-value 0.005
  1. TDI: transition dyspnoea index, SGRQ: St. George's Respiratory Questionnaire